Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 161, 353-60

Pharmacotherapy of Social Phobia. A Controlled Study With Moclobemide and Phenelzine

Clinical Trial

Pharmacotherapy of Social Phobia. A Controlled Study With Moclobemide and Phenelzine

M Versiani et al. Br J Psychiatry.

Abstract

In a double-blind, parallel group trial, 78 subjects with social phobia received moclobemide (a new reversible inhibitor of monoamine oxidase A) phenelzine, or placebo. After eight weeks, both active drugs-phenelzine somewhat more than moclobemide--were clinically and statistically significantly more effective than placebo, as assessed by rating scales. There was some further improvement between weeks 8 and 16, particularly in the moclobemide group; at week 16, 82% of the moclobemide and 91% of the phenelzine-treated patients were almost asymptomatic. Moclobemide was, however, much better tolerated than phenelzine. Patients withdrawn from active drugs had relapsed by week 24, providing additional support for the efficacy of the active drugs.

Similar articles

  • Moclobemide in Social Phobia: A Controlled Dose-Response Trial
    R Noyes Jr et al. J Clin Psychopharmacol 17 (4), 247-54. PMID 9241002. - Clinical Trial
    Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible …
  • Phenelzine vs Atenolol in Social Phobia. A Placebo-Controlled Comparison
    MR Liebowitz et al. Arch Gen Psychiatry 49 (4), 290-300. PMID 1558463. - Clinical Trial
    Seventy-four patients who met DSM-III criteria for social phobia completed 8 weeks of double-blind, randomly assigned treatment with the monoamine oxidase inhibitor phene …
  • Practical Approaches to the Treatment of Social Phobia
    J Clin Psychiatry 55 (8), 367-74. PMID 7915277.
  • Medication Therapy for Social Phobia
    RD Marshall et al. J Clin Psychiatry 55 Suppl, 33-7. PMID 8077172. - Review
    Social phobia, though the third most common psychiatric disorder in the United States, has received little systematic attention until recently. Chronic and disabling symp …
  • Moclobemide in the Treatment of Social Phobia
    D Nutt et al. Int Clin Psychopharmacol 11 Suppl 3, 77-82. PMID 8923114. - Review
    Social phobia is a common disorder which is associated with considerable suffering and impairment. Effective treatments have now been developed and they represent an impo …
See all similar articles

Cited by 28 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback